(Q24606868)

English

Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

0 references

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

Europe PubMed Central

Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis (English)

0 references

0 references

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Jian-ping Zhang

1

object named as

Jian-Ping Zhang

author given names

Jian-Ping

author last names

Zhang

1 reference

PubMed publication ID

20 October 2023

5

object named as

John M Kane

author given names

John M

author last names

Kane

1 reference

PubMed publication ID

20 October 2023

Christoph Correll

6

object named as

Christoph U Correll

author given names

Christoph U

author last names

Correll

1 reference

PubMed publication ID

20 October 2023

author name string

Juan A Gallego

2

author given names

Juan A

author last names

Gallego

1 reference

PubMed publication ID

20 October 2023

Delbert G Robinson

3

author given names

Delbert G

author last names

Robinson

1 reference

PubMed publication ID

20 October 2023

Anil K Malhotra

4

author given names

Anil K

author last names

Malhotra

1 reference

PubMed publication ID

20 October 2023

language of work or name

0 references

publication date

July 2013

0 references

The International Journal of Neuropsychopharmacology

0 references

16

0 references

6

0 references

1205-18

0 references

Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

7 April 2017

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

7 April 2017

Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

7 April 2017

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

7 April 2017

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

7 April 2017

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

7 April 2017

Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

27 September 2017

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

27 September 2017

Past and Present Progress in the Pharmacologic Treatment of Schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

27 September 2017

Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

27 September 2017

Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

27 September 2017

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

27 September 2017

Typical and atypical antipsychotics--the misleading dichotomy. Results from the Working Group 'Drugs in Psychiatry' (AGATE).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

27 September 2017

How neurocognition and social cognition influence functional change during community-based psychosocial rehabilitation for individuals with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

27 September 2017

Lifetime prevalence of psychotic and bipolar I disorders in a general population

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

27 September 2017

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

27 September 2017

Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

27 September 2017

Pharmacological treatments for first-episode schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

27 September 2017

Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

27 September 2017

The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

27 September 2017

Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

27 September 2017

Chlorpromazine equivalent doses for the newer atypical antipsychotics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

27 September 2017

Pharmacologic treatment of schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

27 September 2017

Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001277

21 January 2018

Increased prefrontal cerebral blood flow in first-episode schizophrenia following treatment: longitudinal positron emission tomography study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001277

21 January 2018

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001277

21 January 2018

Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001277

21 January 2018

Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001277

21 January 2018

Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001277

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001277

21 January 2018

Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001277

21 January 2018

Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001277

21 January 2018

Olanzapine versus haloperidol treatment in first-episode psychosis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001277

21 January 2018

Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001277

21 January 2018

Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001277

21 January 2018

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001277

21 January 2018

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001277

21 January 2018

Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

28 November 2018

Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

28 November 2018

A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

28 November 2018

Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

28 November 2018

Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

28 November 2018

Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3594563

28 November 2018

Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23199972

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs

1 reference

https://pubmed.ncbi.nlm.nih.gov/23199972

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The McLean–Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23199972

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Introduction to Meta-Analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001277

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1017/S1461145712001277

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24606868&oldid=1994111683"